Drug Profile
GHRP-1 - QLT USA
Alternative Names: Growth hormone releasing peptide-1 - Atrix LaboratoriesLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Tulane University
- Developer QLT USA
- Class Oligopeptides
- Mechanism of Action Growth hormone releasing factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cachexia; Nutrition disorders; Short stature
Most Recent Events
- 01 Oct 2009 QLT USA has been acquired by Tolmar
- 22 Nov 2004 Atrix Laboratories has been acquired by QLT
- 24 Jun 2004 Phase-I clinical trials in Cachexia in USA (SC)